ABIVAX Société Anonyme/€ABVX

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About ABIVAX Société Anonyme

Abivax Société Anonyme is a clinical-stage biotechnology company headquartered in Paris, France, with a research center in Montpellier and a U.S. office in Waltham, Massachusetts. Founded in December 2013, the company focuses on developing therapeutics that modulate the immune response to treat chronic inflammatory diseases. Its lead drug candidate, obefazimod (formerly ABX464), is in Phase 3 clinical trials for moderately to severely active ulcerative colitis and is being prepared for a Phase 2a trial in Crohn's disease. Abivax collaborates closely with the French National Center for Scientific Research (CNRS), the Institut Curie, and the University of Montpellier. In 2015, the company raised €57.7 million in its initial public offering on Euronext Paris, and in October 2023, it raised €232.3 million through an IPO on the Nasdaq Global Market.

Ticker

€ABVX
Sector
Health Care

Primary listing

PAR

Industry

Biotechnology
Headquarters
Paris, France

Employees

69

ISIN

FR0012333284
Website
www.abivax.com

ABVX Metrics

BasicAdvanced
€451M
-
-€2.94
-
-

Bulls say / Bears say

Abivax's lead drug candidate, obefazimod, has completed enrollment for Phase 3 ABTECT trials in patients with moderately to severely active ulcerative colitis, indicating progress toward potential market approval. (GlobeNewswire)
Analysts have a 'Buy' consensus rating for Abivax, with a 12-month stock price target of $31.5, suggesting a potential upside of over 300% from the current price. (StockAnalysis)
Abivax has presented multiple abstracts on obefazimod at the 2025 European Crohn’s and Colitis Organization Congress, highlighting its commitment to advancing treatments for inflammatory diseases. (StockTitan)
Abivax reported a net loss of €40.82 million for the quarter ending June 2024, reflecting ongoing financial challenges. (Google Finance)
The company's return on assets (ROA) and return on equity (ROE) are negative, indicating inefficiencies in asset utilization and shareholder equity management. (Fintel)
Abivax's stock price has declined by approximately 40.6% over the past year, underperforming the broader US biotech industry. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €ABVX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs